Marstacimab
mAbapprovedOrphan Drug FDA
Approved
Oct 11, 2024
Clinical trial activity
9 trials · 1 clinical orgs · 1 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Aug 1, 2015 (NCT02531815)
Timeline
Indications
Approved for
Mechanism of action
- Tissue factor pathway inhibitorINHIBITOR
Tissue factor pathway inhibitor inhibitor
Kunitz-2
Approval history
- approvedOct 11, 2024
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
First in class
Sources
- ChEMBLCHEMBL3990039 ↗
Also known as
- pf-06741086
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06703606 | Phase 1 | Dec 24, 2024 | Pfizer |
| NCT05611801 | Phase 3 | Dec 9, 2022 | Pfizer |
| NCT05145127 | Phase 3 | Nov 17, 2021 | Pfizer |
| NCT04878731 | Phase 1 | Apr 16, 2021 | Pfizer |
| NCT04832139 | Phase 1 | Mar 30, 2021 | Pfizer |
| NCT03938792 | Phase 3 | Jul 31, 2019 | Pfizer |
| NCT03363321 | Phase 2 | May 30, 2018 | Pfizer |
| NCT02974855 | Phase 2 | Mar 8, 2017 | Pfizer |
| NCT02531815 | Phase 1 | Aug 1, 2015 | Pfizer |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 9 | 9 | 3 | 2015 |
1 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Pfizer | For profit | NDA | Oct 11, 2024 |